Connectome-Based Prediction of Cocaine Abstinence.
Adult
Behavior Therapy
Brain
/ diagnostic imaging
Cholinesterase Inhibitors
/ therapeutic use
Cocaine-Related Disorders
/ complications
Cognition
Connectome
Executive Function
Female
Functional Neuroimaging
Galantamine
/ therapeutic use
Humans
Individuality
Machine Learning
Magnetic Resonance Imaging
Male
Middle Aged
Neural Pathways
/ diagnostic imaging
Opiate Substitution Treatment
Opioid-Related Disorders
/ complications
Prognosis
Reward
Treatment Outcome
Cocaine
Cognitive Neuroscience
Psychoactive Substance Use Disorder
Journal
The American journal of psychiatry
ISSN: 1535-7228
Titre abrégé: Am J Psychiatry
Pays: United States
ID NLM: 0370512
Informations de publication
Date de publication:
01 02 2019
01 02 2019
Historique:
pubmed:
5
1
2019
medline:
22
11
2019
entrez:
5
1
2019
Statut:
ppublish
Résumé
The authors sought to identify a brain-based predictor of cocaine abstinence by using connectome-based predictive modeling (CPM), a recently developed machine learning approach. CPM is a predictive tool and a method of identifying networks that underlie specific behaviors ("neural fingerprints"). Fifty-three individuals participated in neuroimaging protocols at the start of treatment for cocaine use disorder, and again at the end of 12 weeks of treatment. CPM with leave-one-out cross-validation was conducted to identify pretreatment networks that predicted abstinence (percent cocaine-negative urine samples during treatment). Networks were applied to posttreatment functional MRI data to assess changes over time and ability to predict abstinence during follow-up. The predictive ability of identified networks was then tested in a separate, heterogeneous sample of individuals who underwent scanning before treatment for cocaine use disorder (N=45). CPM predicted abstinence during treatment, as indicated by a significant correspondence between predicted and actual abstinence values (r=0.42, df=52). Identified networks included connections within and between canonical networks implicated in cognitive/executive control (frontoparietal, medial frontal) and in reward responsiveness (subcortical, salience, motor/sensory). Connectivity strength did not change with treatment, and strength at posttreatment assessment also significantly predicted abstinence during follow-up (r=0.34, df=39). Network strength in the independent sample predicted treatment response with 64% accuracy by itself and 71% accuracy when combined with baseline cocaine use. These data demonstrate that individual differences in large-scale neural networks contribute to variability in treatment outcomes for cocaine use disorder, and they identify specific abstinence networks that may be targeted in novel interventions.
Identifiants
pubmed: 30606049
doi: 10.1176/appi.ajp.2018.17101147
pmc: PMC6481181
mid: NIHMS1511306
doi:
Substances chimiques
Cholinesterase Inhibitors
0
Galantamine
0D3Q044KCA
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
156-164Subventions
Organisme : NIDA NIH HHS
ID : K01 DA039299
Pays : United States
Organisme : NIDA NIH HHS
ID : P50 DA009241
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA035058
Pays : United States
Références
Front Psychiatry. 2014 Feb 27;5:16
pubmed: 24578695
PLoS One. 2017 Nov 20;12(11):e0184923
pubmed: 29155843
Biol Psychiatry. 2011 Feb 1;69(3):260-5
pubmed: 20965498
Perspect Psychol Sci. 2017 Nov;12(6):1100-1122
pubmed: 28841086
Prog Brain Res. 2016;224:155-73
pubmed: 26822358
Drug Alcohol Depend. 2016 Sep 01;166:134-42
pubmed: 27430401
Nat Neurosci. 2016 Jan;19(1):165-71
pubmed: 26595653
Neuropsychopharmacology. 2013 May;38(6):1085-93
pubmed: 23303067
Mol Psychiatry. 2016 May;21(5):680-5
pubmed: 26260493
Nat Commun. 2018 Jul 18;9(1):2807
pubmed: 30022026
Addict Biol. 2017 Nov;22(6):1790-1801
pubmed: 27600492
J Neurosci. 2016 Sep 14;36(37):9547-57
pubmed: 27629707
Brain Res. 2015 Dec 2;1628(Pt A):147-56
pubmed: 25721787
Neuroimage. 2013 Nov 15;82:403-15
pubmed: 23747961
Neuroimage. 2017 Oct 15;160:140-151
pubmed: 28373122
Nat Neurosci. 2017 Feb 23;20(3):365-377
pubmed: 28230847
Addict Biol. 2012 Nov;17(6):1013-25
pubmed: 22458423
J Subst Abuse Treat. 2017 Jan;72:80-88
pubmed: 27590364
Neuron. 2015 Jan 7;85(1):11-26
pubmed: 25569345
Neuropharmacology. 2013 Jan;64:452-63
pubmed: 22735770
J Clin Psychiatry. 2018 Jan/Feb;79(1):
pubmed: 29286595
Addiction. 2000 Sep;95(9):1335-49
pubmed: 11048353
Biol Psychiatry. 2011 Apr 1;69(7):675-83
pubmed: 21126735
Addiction. 2017 Apr;112(4):719-726
pubmed: 27917536
Biol Psychiatry. 2014 May 1;75(9):746-8
pubmed: 23778288
Biol Psychiatry. 2015 Mar 1;77(5):434-44
pubmed: 25481621
Curr Opin Neurobiol. 2013 Aug;23(4):668-74
pubmed: 23510740
Brain. 2017 May 1;140(5):1513-1524
pubmed: 28334915
Neuropsychopharmacology. 2016 Jul;41(8):2112-21
pubmed: 26792441
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jan 3;80(Pt B):143-154
pubmed: 28322982
Neuroimage. 2012 Oct 1;62(4):2281-95
pubmed: 22326834
Nat Neurosci. 2015 Nov;18(11):1664-71
pubmed: 26457551
Nat Protoc. 2017 Mar;12(3):506-518
pubmed: 28182017
JAMA Psychiatry. 2013 Jan;70(1):87-97
pubmed: 22945462
JAMA Psychiatry. 2015 Jun;72(6):584-92
pubmed: 25853901
Neuroreport. 2001 Dec 4;12(17):3683-7
pubmed: 11726774
Curr Addict Rep. 2016 Sep;3(3):332-342
pubmed: 27990326
Psychol Addict Behav. 2013 Jun;27(2):477-88
pubmed: 22775772
Perspect Psychol Sci. 2009 May;4(3):274-90
pubmed: 26158964